rivatez
I publish patient-facing essays on fertility medicine—arguing for gentler ovarian stimulation in egg freezing and IVF—and short market mentions of select tickers (PGNY, OGN, VITR). Also comment on AI methodology and source limits. Not a financial advisor; views are analytical and informative.
Past bets that played out
Key highlighted call: a repeated patient-facing thesis advocating less aggressive ovarian stimulation in reproductive medicine. The investable read-through: potential to shift patient preferences, clinic protocols, and drug utilization intensity over time, though not a near-term market-moving catalyst.
Patient-facing essay arguing for “gentler” fertility medicine (less aggressive ovarian stimulation) in egg freezing/IVF and positioning current “maximum stimulation” approaches as potentially excessive. Investable read-through: could influence patient preferences, clinic protocols, and drug utilization intensity over time, but it is not a market-moving catalyst by itself.
Patient-facing essay arguing for “gentler” fertility medicine (less aggressive ovarian stimulation) in egg freezing/IVF and positioning current “maximum stimulation” approaches as potentially excessive. Investable read-through: could influence patient preferences, clinic protocols, and drug utilization intensity over time, but it is not a market-moving catalyst by itself.
What this channel is watching now
Active mentions include PGNY (avg conviction 0.56), OGN (avg conviction 0.46), and VITR (avg conviction 0.43). Conviction scores reflect author emphasis across recent posts.
Latest videos and market context
No market or company-specific video content listed. Recent posts are short essays and social commentary rather than traditional video analysis.
strong recommend following this through I dislike calls so I consolidated them to stop breaking up days then I took o...
Post recommends watching a link; discusses disliking calls and restoring a 14th-century church. No market, macro, or company-specific information is provided and no tickers are mentioned.
@LilianPertenava ofc i do!! nice to hear from you after so long. those were good times :) and im really pleased to he...
Personal/social message with no market, macro, sector, company, or ticker content.
@RuxandraTeslo you should consider reading my article in full about the limits of trusting AI models to source data w...
Post is a critique about trusting AI models to source data without primary sources; no market, macro, sector, or company-specific claims are made and no tickers are referenced.
@RuxandraTeslo hello again yep, the image error you flagged is real - one AI generated image among dozens in a 13k wo...
Post discusses a minor factual error in an AI-generated image within a long essay (wrong cycle day number) while stating the written protocol timing is correct; mentions methodology section covering AI use/limits. No market-relevant or tradable information.
Proof-backed call history
Published multiple patient-facing essays on fertility care advocating for gentler approaches versus maximum stimulation. Also posts on AI limits, methodology, and occasional personal/social messages.
Patient-facing essay arguing for “gentler” fertility medicine (less aggressive ovarian stimulation) in egg freezing/IVF and positioning current “maximum stimulation” approaches as potentially excessive. Investable read-through: could influence patient preferences, clinic protocols, and drug utilization intensity over time, but it is not a market-moving catalyst by itself.
Patient-facing essay arguing for “gentler” fertility medicine (less aggressive ovarian stimulation) in egg freezing/IVF and positioning current “maximum stimulation” approaches as potentially excessive. Investable read-through: could influence patient preferences, clinic protocols, and drug utilization intensity over time, but it is not a market-moving catalyst by itself.
Patient-facing essay arguing for “gentler” fertility medicine (less aggressive ovarian stimulation) in egg freezing/IVF and positioning current “maximum stimulation” approaches as potentially excessive. Investable read-through: could influence patient preferences, clinic protocols, and drug utilization intensity over time, but it is not a market-moving catalyst by itself.
About this channel
I write accessible essays on fertility medicine and occasionally discuss selected equities. My work emphasizes methodology and the limits of AI-sourced material. Recommendations are intended as research perspectives, not investment advice.
@rivatez
Most recognized assets
Unlock the full track record
Follow @rivatez for essays on reproductive medicine, methodological commentary about AI, and occasional ticker-focused notes on PGNY, OGN, and VITR.